In each participant country 3-3-3-3 interviews with payers, rheumatologists, patients/patient representatives, and industry representatives were conducted. Methods: A detailed interview guide was developed based on multi-stakeholder workshops and a targeted literature review. Our objective was to explore these access barriers for tumor necrosis factor (TNF) alpha inhibitors in rheumatoid arthritis (RA) in five Central and Eastern European countries. Hidden access barriers may facilitate financial sustainability of pharmaceuticals in less affluent EU countries however, they have rarely been documented in scientific publications. Introduction: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. 10National Institute of Rheumatology and Physiotherapy, Budapest, Hungary.9Erasmus School of Health Policy and Management, Erasmus University of Rotterdam, Rotterdam, Netherlands.8OAKS Consulting s.r.o., Prague, Czechia.
7Syreon Research Romania, Tirgu Mures, Romania.6Faculty of Technical and Human Sciences, Sapientia University, Tirgu Mures, Romania.4Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.3Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, Slovakia.2Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.1Syreon Research Institute, Budapest, Hungary.András Inotai 1,2, Dominik Tomek 3, Maciej Niewada 4,5, László Lorenzovici 6,7, Martin Kolek 8, Jakub Weber 8, Anne-Katrin Kurrat 9, Emese Virág Kiss 10 and Zoltán Kaló 1,2*
0 kommentar(er)
